Skip to content
wua. Sweden
English

Fluazinam: EFSA reopens scrutiny after researchers challenge old study

AI-generated editorial illustration; this is not a photograph of the event.
Produced by wua.life

EFSA is reviewing fluazinam information again after two Stockholm University researchers alleged that six results were incorrectly reported in a 20-year-old, industry-commissioned study. The immediate development is the renewed regulatory scrutiny, not a final finding on health risk.

DN reports that fluazinam is widely used against fungal disease on Swedish and European potato fields. Researchers Axel Mie and Christina Rudén say they reran parts of the older study’s statistical analysis and concluded that exposed rat pups showed adverse effects on brain development at every tested dose. They argue that the findings may matter for children living near potato fields, where spray drift could create exposure.

That is a serious challenge to evidence used in pesticide oversight. When a safety study is alleged to contain wrongly reported results, regulators should examine both the data and the route by which it entered, or failed to enter, their assessment. EFSA’s decision to review information from manufacturer ISK Biosciences again is therefore an appropriate response.

The claim still has important limits. The researchers’ paper is a preprint awaiting peer review. The supplied reporting does not include the full raw data, the precise nature of all six alleged errors, or measurements of children’s real-world exposure near Swedish fields. Those gaps prevent a firm conclusion about human health effects or the likely outcome of the regulatory process.

ISK Biosciences previously told SVT that it was aware of the researchers’ allegations, that the original study had been reviewed by authorities and that it had confidence in established regulatory processes. That is the strongest relevant counterargument, and it makes a transparent EFSA review essential: the agency should explain how it weighs the competing interpretations.

Sweden’s Chemicals Agency is also reassessing fluazinam, with a decision expected in April 2028, according to DN. The central test now is whether EFSA’s review addresses the researchers’ specific allegations before further regulatory decisions are made.

Sources

Independent editorial content. WUA is not affiliated with any political party. 2026-11-18